Partners

DNDi has various types of agreements with its partners worldwide, such as Technical Agreements, Material Transfer Agreements, Research and License Agreements, R&D Agreements, Clinical Trial Agreements, and Financial Agreements.

Technical Agreements regulate financial transactions for precise services within a contractual framework. Material Transfer Agreements provide access to compounds for testing in which no access clause with the provider is negotiated. In addition to these Agreements, DNDi seeks to conclude Research and License Agreements with key partners which involve a greater commitment from both parties. The core of these agreements concern IP ownership (generally owned by the partner and in some cases co-owned), and licensing clauses. Several conditions are required to ensure availability and affordability of the treatment and respect of DNDi’s IP policy objectives. As a not-for-profit and patient-needs driven organization, DNDi seeks transparency to efficiently address urgent patient needs. Therefore, the licenses should be:

• royalty-free to ensure the lowest possible price
• sub-licensable, or in other terms, contain the authorization to disclose the obtained information to another party in order to continue product development
• worldwide coverage both for R&D and for manufacture
• non-exclusive to enable third parties to enter the field (included in our most innovative agreements)
• limited confidentiality to make available all information generated on the product during its development in the form of publications or databases.

Pharmaceuticals
Biotechs
Universities
University "Spin-off"
Research institutes
National Research Centres
NGOs/IOs
PDPs/PPPs
Hospitals
Ministries of Health/Governmental organizations
Contract Research Organizations (CROs)

Pharmaceuticals

ABBOTT, global, broad-based health care company (USA). Since February 2009, compounds provider for research on Chagas disease, HAT and leishmaniasis.

CIPLA, Chemical, Industrial and Pharmaceutical Laboratories specialized in generics (India). Since January 2007, DNDi partner against malaria, by developing and producing the combination of the product (ASMQ) as well as file application, registration and distribution in endemic countries at cost (in the public sector).

Debiopharm, Global biopharmaceutical development specialist that in-licenses promising biologicals and small molecule drug candidates (Switzerland). Material transfer agreement, beginning April 2011, for discovery activities.

Eisai, a research-based health care company (Japan). Since September 2009, DNDi partner through collaboration and license agreement on clinical studies for Chagas disease using the E 1224 compound. Eisai has the option of becoming a pharmaceutical partner for manufacturing and distribution.

Farmanguinhos, Institute of technology in pharmaceuticals; scientific and technical branch of the Oswaldo Cruz foundation (Fiocruz), official laboratory of the Ministry of Health (Brazil). Since 2006, various agreements for production and distribution of ASMQ at cost in endemic countries.

GILEAD, biopharmaceutical company (USA). Since 2008, donation program of ambisome for clinical studies on VL.

GNF Novartis, Genomics Institute of the Novartis Research Foundation (USA). Since October 2009, DNDi partner for discovery phase on kinetoplastids.

GSK, Tres Cantos - Open Lab Foundation, (Spain). Since May 2006, various partnerships through screening, discovery activities, and clinical trials for CL.

HIKMA, a generic manufacturer (Jordan). LoI to engage in further collaborations in the field of Leishmaniasis, HAT, and Chagas disease.

LAFEPE, Laboratorio Farmacêutico do Estado de Pernambuco, public laboratory (Brazil). Since June 2008, Preclinical agreement and collaboration agreement for Chagas disease: to manufacture the paediatric formulation of benznidazole.

Merck & Co., pharmaceutical company (USA). Since 2008, Merck granted access to compounds through a non-exclusive, worldwide license, for research on NTDs.

Paladin Labs, pharmaceutical company (Canada). Since 2009, Paladin Labs provides miltefosine for clinical studies on VL in Eastern Africa.

Pfizer Limited, pharmaceutical company (UK). Since 2004: material transfer agreement to provide amodiaquine for ASAQ; 2009, research and license agreement to access compound libraries.

Sanofi, pharmaceutical company (France). Since 2004, DNDi partner through manufacture, registration, and distribution partner for ASAQ in endemic countries. Since January 2011, R&D license agreement to allow research and development on various NTDs, aiming to provide affordable treatments in endemic countries of low -middle income economies and Latin America.

Zenufa Laboratories Ltd, pharmaceutical manufacture and distribution (Tanzania). Since March 2011, recipient of DNDi’s technology transfer of ASAQ. Partner for manufacture and distribution.

...

top of the page


Biotechs

Anacor, biopharmaceutical company (USA). Since December 2007, DNDi partner through research collaboration and license agreement to provide compounds of the oxaborole class for research on HAT, VL-CL, and Chagas disease.

Genzyme, biotechnology company part of the Sanofi group (USA): material transfer for research and development on HAT, Chagas disease, and Leishmaniasis.

Evolva, biotechnology company (Switzerland). Since 2008, DNDi partner in discovery for kinetoplastids.

Polytherics, biotechnology company (UK). Since October 2006, DNDi partner on formulation of amphotericin B, in collaboration with Imperial College.

Scynexis, drug discovery and development company (USA). Since December 2005, DNDi partner through screening and material transfer for research and development on kinetoplastids.

Vertex, pharmaceutical company (USA). Since January 2010, DNDi partner through material transfer agreement for R&D, in the field of kinetoplastids.

...

top of the page


Universities

Addis Ababa University (Ethiopia), Leishmaniasis East Africa Platform (LEAP) partner. Since April 2005, clinical trial partner for leishmaniasis.

Antwerp University, Laboratory of Microbiology, Parasitology and Hygiene (Belgium). Since June 2006, DNDi partner for screening and discovery activities.

Brasilia University (Brazil). DNDi partner for clinical trials for VL.

Dundee University, Research and Innovation Services (UK). Since 2004, DNDi partner through research and development license agreement on HAT, and Leishmaniasis.

FAPUNIFESP, Fundaçao de Apoio Universidade Federale de Sao Paolo (Brazil). Since March 2009, DNDi partner in the field of Chagas disease.

Gondar University Hospital (Ethiopia). Leishmaniasis East Africa Partner (LEAP) partner. Since March 2005, DNDi partner for clinical trials for VL.

Imperial College (UK). Since October 2006, DNDi partner on formulation of amphotericin B with Polytherics.

London School of Pharmacy (UK). Since October 2006, partner on formulation of amphotericin B, in collaboration with Imperial College.

LSHTM, London School of Hygiene and Tropical Medecine (UK). Since January 2005, DNDi partner for screening, clinical trials and discovery in the field of Leishmaniasis.

Makerere University and Amudat Hospital (Uganda). Since November 2008, DNDi partner for clinical trials for VL.

Monash University, Centre for Drug Candidate Optimization (Australia). Since July 2008, DNDi partner through a technical agreement for Chagas disease.

Murdoch University, School of Veterinary and Biomedical Science (Australia). Since August 2006, technical agreement, and since July 200, R&D agreement on Chagas disease.

Pace University (USA). Since April 2007, DNDi partner for pre-clinical studies in the field of HAT.

Prince Leopold Institute for Tropical Medicine (Belgium). Since September 2006, DNDi partner for HAT, malaria and since May 2011, partner for clinical trials on VL, and HIV co-infected patients.

UCSF, University of California, San Francisco (USA). Since January 2011, DNDi partner for pre-clinical studies on Chagas disease.

University of Auckland (New Zealand). In 2009, DNDi partner for HAT, and since 2010, partner on VL.

Universidad Mayor de San Simon (Bolivia). DNDi partner for clinical trials for Chagas disease.

University of North Carolina, Office of Technology Development (USA). Since 2007, DNDi partner through information sharing and discovery for NTDs.

Universidade Ouro Preto (Brazil). Since April 2005, DNDi partner in the field of Chagas disease through discovery and R&D agreement.

University of Oxford, Worlwide Antimalarial Drug Resistance Network (UK). Since October 2009, DNDi partner through data collection on malaria.

University Sains (Malaysia). Since April 2004, DNDi partner on malaria.

...

top of the page


University "Spin-off"

Epichem, product and service provider in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. (Australia). Since 2008, provides medicinal chemistry lead optimization for series on kinetoplastids.

Eskitis, The Eskitis Institute for Cell and Molecular Therapies. Griffith University (Australia). Since 2009, partner on drug discovery for HAT.

top of the page


Research institutes

ASK: AMC (Academic Medical Center), Slotervaart Hospital, KIT (Royal Tropical Institute), (The Netherlands). Since 2009, DNDi partner for clinical trials for VL.

Broad Institute, MIT and Harvard (USA). Since September 2010, DNDi partner through discovery activity for Chagas disease.

CRESIB, Centre de Recerca en Salut Internacional de Barcelona (Spain). Since September 2010, DNDi partner for the clinical phase for Chagas disease.

FIPEC: Fundacion Para el Estudio de las Infecciones Parasitarias y enfermedad de Chagas (Argentina). Since 2010, DNDi partner on clinical studies for Chagas disease.

Georges Institute for International Health (Australia). Since May 2009, DNDi partner through research.

IMEA Consulting France : Institut de Médecine et d'Epidémiologie Appliquée, Département de Santé Tropicale (France). Since January 2010, DNDi partner for clinical phase of ASAQ (malaria).

IEND, Institute of Endemic Disease, Khartoum University (Sudan), Leishmaniasis East Africa Platform (LEAP). Since December 2004, DNDi partner for clinical trials for VL Combo.

IRD, Institut de Recherche pour le Développement (France). Since 2007, various partnerships on VL and currently partner for clinical trials of ASAQ (malaria).

Institut Pasteur (France). Since December 2008, discovery and screening partner for leishmaniasis.

Institut Pasteur Korea (Korea). Since April 2008, DNDi partner on Chagas disease and leishmaniasis for high throughput screening and discovery activities.

Institut René Rachou IdP (Brazil). Since October 2007, DNDi partner for pre-clinical studies for VL.

KEMRI, Kenyan Research Medical Institute (Kenya). Since January 2005, various partnerships for clinical trials of malaria (ASAQ and ASMQ) as well as VL.

Seattle Biomedical Research Institute (USA). Since October 2008, DNDi partner for discovery on NTDs.

Swiss Tropical and Public Health Institute (Switzerland). Since 2006, various partnerships through discovery, screening (kinetolastids), and clinical trials for HAT, leishmaniasis.

...

top of the page


National Research Centres

B.P Koirala Institute of Health Sciences (Nepal). DNDi partner for clinical trials for VL.

CNRFP, Centre National de Recherche et de Formation sur le Paludisme (Burkina Faso). Since August 2010, DNDi partner for clinical trials for malaria.

CSIR, Council of Scientific and Industrial Research (India). Since August 2008, various partnerships for leishmaniasis and HAT through screening and discovery activities of anti-leishmaniasis compounds.

CDRI, Central Drug Research Institute (India). Since June 2007, various discovery partnerships for leishmaniasis and HAT.

Fiocruz, Fundaçao Oswaldo Cruz (Brazil). Since 2003, various partnerships through information sharing, discovery, clinical trials, research on malaria (ASMQ) and Chagas disease.

ICDDR, International Centre for Diarrheal Disease Research (Bangladesh). Since November 2009, DNDi partner for clinical trials for VL.

ICMR, Indian Medical Research Council (India). Since 2006, DNDi partner for clinical trials for VL.

Kala Azar Medical Research Center (India). Since January 2007, DNDi partner for clinical trials for VL.

RMRIMS, Rajendra Memorial Research Institute of Medical Sciences (India). DNDi partner for clinical trials for VL.

...

top of the page


NGOs/IOs

AEDES, consulting firm for Social and Public health sector (Belgium). In 2008, partner for malaria CMC manufacture. Since January 2011, partnership for the technology transfer of ASAQ to Zenufa.

CEADES, Collective of Applied Studies and Social Development (Bolivia). Since September 2010, DNDi partner for clinical trials of benznidazole against Chagas disease.

Epicentre, non-for-profit organization which groups health professionals specialized in public health/epidemiology (France). Since November 2005, various partnerships for clinical phases on malaria and HAT.

IDA Foundation (The Netherlands). Since December 2008, DNDi partner for clinical phase for VL.

i+solutions (The Netherlands). Continuation of the partnership with IDA Foundation: Leishmaniasis East Africa Platform (LEAP) partner.

Médecins Sans Frontières: Since 2003, various partnerships in financing, discovery, and clinical trials.

OTECI, Offre Technique d’Etude et de Coopération Internationale (France). Since January 2008, DNDi partner through technology transfer support for ASMQ (malaria).

WHO-TDR: World Health Organization, TDR, Special Programme for Research and Training in Tropical Diseases and co-sponsored by UNICEF, UNDP, the World Bank and WHO. Founding partner since 2003. Various collaboration projects on malaria and kinetoplastids.

...

top of the page


PDPs/PPPs

FIND, Foundation for Innovative New Diagnostics (Switzerland). Since August 2010, collaboration and material transfer agreement to develop an ELISA-based diagnostic test for leishmaniasis.

iOWH, Institute for One World Health (USA). Since April 2009, DNDi partner for VL.

MMV, Medicines for Malaria Venture (Switzerland). Since September 2004, various partnerships through information sharing, discovery on malaria.

NITD Novartis Institute for Tropical Diseases (Singapore). Since April 2007, partnership in discovery on kinetoplastids.

TB Alliance: Global Alliance for Tuberculosis Drug Development (USA). Since January 2007, various partnerships through screening and discovery in the field of kinetoplastids.

TI Pharma, public-private partnership (The Netherlands). DNDi partner for discovery activities.

...

top of the page


Hospitals

Arba Minch Hospital (Ethiopia). Leishmaniasis East Africa Platform (LEAP) partner. Since April 2005, clinical trial Agreement for VL.

CHUV, Centre Hospitalier Universitaire Vaudois (Switzerland). Since June 2009, technical agreement for discovery.

KATH, Komfo Anokye Teaching Hospital (Ghana). Since 2008, DNDi partner for access and data management for ASMQ (malaria).

Shaheed Suhrawardy Medical College and Hospital (Bangladesh). Since November 2009, DNDi partner for clinical trials for VL.

...

top of the page


Ministries of Health/Governmental organizations

Ministry of Health (Brazil). DNDi partner for clinical trials for VL.

Ministry of Health (Cambodia). Since July 2010, DNDi partner for clinical research in the field of malaria.

Ministry of Health (Ethiopia). Since 2004, Leishmaniasis East Africa Platform (LEAP) partner.

Ministry of Health (Kenya). DNDi partner for clinical trials for VL.

Ministry of Health (Rep. Dem. Congo). Since January 2006, various partnerships (financial and clinical trial agreement) in the field of HAT.

Ministry of Health (Uganda). Since 2004, Leishmaniasis East Africa Platform (LEAP) partner.

CeNDIE, Centro Nacional de Diagnostico e Investigacion de Endemo-epidemias, Ministry of Health, (Argentina).

Gedarif MoH (Sudan). Leishmaniasis East Africa Platform (LEAP). Since December 2004, various partnerships for clinical trials in the field of leishmaniasis.

National Trypanosomiasis Control Programmes (Republic of Congo and Democratic Republic of Congo). DNDi partners for clinical trials for HAT.

...

top of the page


Contract Research Organizations (CROs)

Accelera (Italy). Since September 2007, works with DNDi on pre-clinical studies.

Advinus Therapeutics (India). Since January 2006, various partnerships through discovery-, pre-clinical-, lead optimization and clinical activities.

Aptuit (UK). Since December 2008, research services agreement concerning pre-clinical activities as well as CMC and manufacture phases.

Bertin Pharma (France). Since March 2011, works with DNDi for capacity strengthening and technology transfer of ASAQ to Zenufa in Tanzania.

Cardinal System (France). Since January 2004, works with DNDi: screening, lead optimization, and clinical activities in the field of malaria and other NTDs.

Catalent (USA). Since November 2007, works with DNDi: screening, discovery, clinical activities as well as registration and regulatory issues in the field of malaria.

Centipharm (France). Since November 2007, works with DNDi: CMC/manufacture of fexinidazole for HAT.

CONICET INGEBI (Argentina). Since October 2010, works with DNDi for clinical phases in the field of Chagas disease.

CoreLab Partners (USA). Since April 2011, works with DNDi for clinical activity for Chagas disease.

Drugabilis (France). Since January 2009, works with DNDi for pre-clinical activity.

GVK Biosciences (India). Since October 2006, works with DNDi in the clinical phase for malaria and VL.

LAT Research (Argentina). Since December 2010, works with DNDi on the clinical studies of benznidazole against Chagas disease.

Penn Pharmaceuticals Services (UK). Since May 2010, works with DNDi on pre-clinical study (formulation) for HAT.

RCTs (France). Since May 2009, works with DNDi on clinical study of NECT for HAT.

SGS Aster SAS (France). Since November 2008, works with DNDi for clinical study of fexinidazole for HAT.

...


Please contact us at partnership@dndi.org to propose collaborative projects.

top of the page